Compare

Helus Pharma/$HELP

1D1W1M3M6MYTD1Y5YMAX

About Helus Pharma

Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Ticker
$HELP
Sector
Health
Primary listing
NASDAQ
Employees
100
Headquarters
Toronto, Canada
Website
www.helus.com

Helus Pharma Metrics

BasicAdvanced
$686M
-
-$4.05
0.62
-

Bulls say / Bears say

Earlier Phase 2 results for HLP003 showed a mean 23-point reduction in depression scores at 12 months, with 71% remission using the stated benchmark. This is an encouraging early signal for its lead programme, though it still needs confirmation in larger trials. (Helus Pharma)
The pivotal APPROACH trial finished enrolling ahead of schedule, with top-line results expected in Q4 2026. HLP003 also has FDA Breakthrough Therapy designation, giving investors a near-term catalyst and an expedited review pathway if the evidence supports it. (Helus Pharma)
HLP004 offers a second potential product for generalised anxiety disorder: Helus reported an early improvement in its Phase 2 signal-finding study and plans a controlled Phase 2 study in Q1 2027. This broadens the pipeline beyond HLP003 and targets a condition with limited treatment options. (Helus Pharma, Helus Pharma)
The investment case depends heavily on HLP003 succeeding in a pivotal trial; the earlier Phase 2 findings do not prove that the larger Phase 3 study will work. A disappointing result could undermine the lead programme and the share price. (Helus Pharma, SEC)
Helus is spending heavily before it has product revenue: it reported $37.1 million of operating cash outflow and a $47.8 million net loss in its latest quarter. Continued losses may require further financing and dilute existing shareholders. (Helus Pharma, SEC)
Positive trial data would not itself secure approval or sales: Helus still expects to file an HLP003 application in 2028, and its filings warn of regulatory, commercialisation and market-acceptance risks. That leaves a long, uncertain path before the company could generate meaningful product revenue. (Helus Pharma, SEC)
Data summarised monthly by Lightyear AI. Last updated on 29 Oct 2026.

Helus Pharma News

AllArticlesVideos

Cybin Expects Key Phase III Depression Trial Results This Quarter

MarketBeat3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.